S4-3.1 – NASH-TAG Review: Patient Advocate Panel on Influence of New Drugs and Interprofessional Collaboration

S4-3.1 - NASH-TAG Review: Patient Advocate Panel on Influence of New Drugs and Interprofessional Collaboration
Surfing NASH highlights key moments from its coverage of a historic NASH-TAG conference. In this conversation, patient advocates Tony Villiotti and Michael Betel discuss how new information and successful drug trials are changing demand from physicians, patients and caregivers.

NASH-TAG 2023 proved to be a watershed moment for Fatty Liver disease as exciting drug development readouts, powerful academic work on non-invasive tests and the willingness to dive into the toughest questions aligned in Deer Valley, Utah. In this weekend’s conversation series, Surfing NASH reviews its diverse coverage of the conference by showcasing key excerpts across six recordings with various KOLs, patient advocates and stakeholders.

This conversation features our patient advocate discussion with NASH kNOWledge founder, Tony Villiotti, and Fatty Liver Alliance Founder and CEO, Michael Betel.

Tony and Michael begin by describing the high levels of enthusiasm that began at AASLD and carried through to NASH-TAG as it became clear that there are drug trials appearing to meet all criteria for approval. Louise Campbell extends this sentiment further, commenting that new medications combined with greater awareness of the breadth of integrated metabolic disease is leading to a surge in collaboration with other specialists. Specifically, she refers to the involvement of cardiology and endocrinology specialists as a “game changer.”

Michael shifts focus to the idea that patients with diabetes and/or obesity might be taking GLP-1s or dual glucagon agents for those diseases. He points out that should new NASH drugs be approved, this might lead to de facto combination therapy. Louise suggests reasons why this might be a double-edged sword. The remainder of the episode focuses on things we do not know about the drugs – how they interact, how long they will work and what downsides may be. Louise offers a final thought which emphasizes the importance of providing professional and patient education and training to make sure the new medicines are used properly.

Experience Nudge Learning! Interested in a new way of learning?